VIDEO: Study shows higher doses of upadacitinib produce added benefit in moderate-to-severe AD
- Jeremy Visser
- Jan 5, 2022
- 1 min read
Higher doses of upadicitinib show added benefits for adults with moderate-to-severe atopic dermatitis (AD) when compared to dupilumab, according to a new study.
Commentaires